IR Viloxazine
812P201
Phase 2 small_molecule completed
Quick answer
IR Viloxazine for Attention-Deficit/Hyperactivity Disorder (ADHD) is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed